SequelSEC

Ceribell, Inc. CBLL

Electromedical & Electrotherapeutic Apparatus · CIK 0001861107 · Fiscal year ends 1231

Revenue
$89.06M
Fiscal year ended 2025-12-31
Operating income
-$58.40M
Fiscal year ended 2025-12-31
Free cash flow
-$41.58M
Fiscal year ended 2025-12-31

Ceribell, Inc. (CBLL) reported revenue of $89.06M and net income of -$53.41M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Ceribell, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

Ceribell, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Revenue$89.06M$65.44M$45.22M
Cost of revenue$10.79M$8.69M$7.06M
Gross profit$78.27M$56.75M$38.16M
Operating income-$58.40M-$39.71M-$30.04M
Net income-$53.41M-$40.46M-$29.46M
Research & development$19.14M$13.56M$9.00M
Weighted-average diluted sharesshares 36.54Mshares 11.95Mshares 5.30M
Pretax income-$53.41M-$40.46M-$29.45M
Income tax expense$0$0$11.00K
Diluted EPS$-1.46$-3.39$-5.56
Selling, general & administrative$117.53M$82.90M$59.21M
General & administrative$44.45M$33.84M$20.29M
Selling & marketing$73.08M$49.06M$38.92M

Balance

Ceribell, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$40.48M$194.37M$34.50M
Total assets$195.80M$225.41M$58.92M
Current assets$186.72M$217.27M$51.96M
Total liabilities$40.47M$34.25M$23.76M
Current liabilities$19.19M$12.99M$21.60M
Total equity incl. NCI$155.34M$191.16M-$112.25M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
Inventory$7.29M$6.94M$5.87M
Accounts receivable$15.05M$10.88M$7.96M
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$2.84M$1.14M$732.00K

Cash flow

Ceribell, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$40.81M-$35.04M-$29.16M
Capital expenditures$767.00K$1.34M$983.00K
Investing cash flow-$118.14M-$1.60M-$1.76M
Financing cash flow$5.05M$196.52M-$2.82M
Net change in cash-$153.89M$159.88M-$33.74M
Stock-based compensation$12.22M$5.41M$2.68M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortization$1.34M$1.14M$847.00K

Derived

Ceribell, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$41.58M-$36.38M-$30.14M
Gross margin87.9%86.7%84.4%
Operating margin-65.6%-60.7%-66.4%
FCF margin-46.7%-55.6%-66.6%
SBC / revenue13.7%8.3%5.9%
Current ratio9.73x16.73x2.41x
Revenue YoY growth36.1%44.7%Unavailable
Net margin-60.0%-61.8%-65.1%
R&D / revenue21.5%20.7%19.9%
CapEx / revenue0.9%2.0%2.2%
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CBLL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-12-31

Difference 147412000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.